A negative reaction to positive migraine data sends Biohaven down.
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
Though the stage is apparently set for Bristol’s contingent value right to pay out, the instrument trades at depressed levels.
All of Vantage's Covid-19 stories in one place: share price reactions, clinical trial delays, cost estimates, and more. This page will be updated as our coverage…
Silence has received an important validation, but making progress could be tough.
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.